<DOC>
	<DOCNO>NCT00787566</DOCNO>
	<brief_summary>Brief Summary : A randomized , single administration , double-blind , parallel- group Phase 2 dose find study ass efficacy , tolerability , safety TRG patient chemotherapy-induced nausea vomiting ( CINV ) associate administration highly emetogenic chemotherapy . Primary Objective : To select dose Phase 3 assess efficacy , safety , tolerability 3 dos TRG patient CINV associate administration highly emetogenic chemotherapy .</brief_summary>
	<brief_title>Phase 2 Study Efficacy , Tolerability , Safety Intranasal Granisetron Chemo-Induced Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Patients histologically and/or cytologically confirm cancer ECOG performance status 0 , 1 , 2 Patients life expectancy least 3 month Patients chemotherapy na√Øve Patients receive first cycle highly emetogenic regimen accord MASCC criterion Hesketh criterion Patients adequate metabolic hematologic value chemotherapy Patients intact nasal mucosa Non childbearing potential patient Patients able read write competent level , capable give legal consent Patients provide write informed consent Patients receive chemotherapy regimen highly emetogenic chemotherapy regimen accord MASCC Hesketh criterion Patients nasal cancer , pharyngeal cancer , maxillary sinus cancer , ethmoid sinus cancer Patients nasal ulcer , septal perforation , nasal condition may interfere IN administration Patients episode retching , vomit , uncontrolled nausea within 48 hour dose TRG and/or administration chemotherapy Patients receive radiation therapy 14 day dose TRG , radiation therapy schedule 7 day TRG dose Patients receive investigational product within 30 day prior study entry Patients receive drug schedule receive drug antiemetic efficacy within 24 hour start treatment Patients allergy hypersensitivity granisetron selective 5hydroxytryptamine3 ( 5HT3 ) receptor antagonists Patients ECOG performance status 3 4 Patients history brain tumor , head cancer , neck cancer Patients psychological problem , Investigator 's opinion , severe enough interfere study eligibility interpretation study result Patients pregnant ( urine test ) breastfeeding Patients receive prior cytotoxic chemotherapy give treatment cancer Patients schedule receive multiple day chemotherapy Patients clinically relevant abnormal laboratory value discretion Investigator Patients clinically relevant hepatic , renal , infectious , neurological , psychiatric disorder , major systemic illness discretion Investigator Patients prevalence cause nausea vomit chemotherapy Patients use systemic steroid indication , patient use steroid dexamethasone prevention chemotherapyinduced nausea vomiting , patient use dexamethasone chemotherapyinduced nausea vomiting dos recommend MASCC antiemetic guideline Patients QT interval great 500 m acute ischemic change cardiac abnormality predispose arrhythmia screen electrocardiogram ( ECG ) history Patients history drug and/or alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Highly emetogenic chemotherapy induce nausea vomiting</keyword>
</DOC>